On April 20, 2022 EpiAxis Therapeutics reported that it was thrilled to attend and present at the ACCESS CHINA Biotech Forum Spring Showcase 2022 earlier this month (Press release, EpiAxis Therapeutics, APR 20, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-therapeutics-presents-access-china [SID1234612827]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ACCESS CHINA Biotech Forum is one of the largest corporate access events in China. It provides opportunities for business development, licensing deals and commercial collaborations to global biopharmas. It has been held every quarter since 2020 and has been bringing together international and Chinese biotech BDs and CEOs over the past two years.
The 2022 ACCESS CHINA forum was held online from 18-19 April 2022, attracting more than 1000 participants from China pharma and biotech companies.
EpiAxis CEO Dr Jeremy Chrisp presented during the US and Australia biotech Company Roadshows sessions. His video presentation focused on overcoming resistance to standard of care cancer treatments with novel epigenetic cancer therapies.
Dr Chrisp explained that the primary focus at EpiAxis Therapeutics is the initial treatment and subsequent prevention of recurrence of cancer using proprietary LSD1 inhibitors.
"We are seeking capital to allow us to complete our program to advance one of our therapeutics into the clinic," Dr Chrisp said. "We believe LSD1 is the pivotal enzyme controlling cancer regression. Our thesis is directed towards inhibiting nuclear LSD1 and we believe it allows us to reprogram cancer cells and immune cells to offer a new way to treat aggressive cancer."